Prostate Cancer Drugs Market Report 2026

Prostate Cancer Drugs Market Overview

• Prostate Cancer Drugs market size has reached to $19.51 billion in 2025 • Expected to grow to $26.15 billion in 2030 at a compound annual growth rate (CAGR) of 6.2% • Growth Driver: Increasing Geriatric Male Population Driving Market Growth Due to Higher Disease Prevalence and Rising Treatment Demand • Market Trend: Innovative Products Gain Approval From Federal Agencies For Prostate Cancer Treatment • North America was the largest region in 2025 and Middle East is the fastest growing region.

What Is Covered Under Prostate Cancer Drugs Market?

The prostate cancer drugs refer to drugs that are used for the prevention and treatment of prostate cancer. Prostate cancer is one of the most common types of cancer caused due to uncontrollable development of cells in the prostate gland in men that produces the seminal fluid that nourishes and transports sperm. Some of the possible treatments for prostate cancer include hormonal therapy, chemotherapy, immunotherapy, and targeted therapy. The different types of prostate cancer drugs are hormone-sensitive prostate cancer and hormone-refractory prostate cancer. Hormone-refractory prostate cancer (HRPC) is a kind of prostate cancer that no longer responds to hormone therapy, even newer treatments. The different types of therapies include hormonal therapy, chemotherapy, immunotherapy, and targeted therapy and involve various sectors such as hospitals, clinics, and others.

What Is The Prostate Cancer Drugs Market Growth Forecast?

The prostate cancer drugs market size is expected to see strong growth in the next few years. It will grow to $26.15 billion in 2030 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to growth in targeted and immunotherapy drugs, rising incidence of advanced prostate cancer, increasing treatment personalization, expanding healthcare access, growth in oncology spending. Major trends in the forecast period include rising use of hormonal therapy in early treatment, increased adoption of targeted prostate cancer drugs, growing focus on castration-resistant prostate cancer, expansion of combination therapy approaches, increased hospital-based prostate cancer care.

Global Prostate Cancer Drugs Market Segmentation

1) By Type: Hormone Sensitive Prostate Cancer, Hormone Refractory Prostate Cancer 2) By Therapy: Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy 3) By End User: Hospitals, Clinics, Other End-Users Subsegments: 1) By Hormone Sensitive Prostate Cancer: Early-Stage Prostate Cancer, Locally Advanced Prostate Cancer, Metastatic Prostate Cancer 2) By Hormone Refractory Prostate Cancer: Castration-Resistant Prostate Cancer (CRPC), Metastatic Castration-Resistant Prostate Cancer (mCRPC)

What Are The Drivers Of The Prostate Cancer Drugs Market?

The increasing men geriatric population is expected to propel the growth of the prostate cancer drugs market going forward. The men geriatric population refers to the segment of the male demographic aged 65 and older, who typically experience an increased prevalence of age-related health conditions and require specialized medical attention. This rise in the aging male population is due to improved healthcare access, declining mortality rates, and longer lifespans globally. The increasing geriatric male population supports the prostate cancer drugs by expanding the number of patients requiring hormonal therapies, immunotherapies, chemotherapy, and targeted medicines for disease management and survival improvement. For instance, in February 2025, according to the World Health Organization, a Switzerland-based international public health organization, global life expectancy at birth reached 73.3 years in 2024 and the number of people aged 60 and older worldwide is projected to rise from 1.1 billion in 2023 to 1.4 billion by 2030. Therefore, increasing men geriatric population is driving the growth of the prostate cancer market. The rising incidence of prostate cancer is expected to propel the growth of the prostate cancer drugs market going forward. Prostate cancer is a malignant condition that develops in the prostate gland, requiring effective and timely treatment to reduce complications and improve patient outcomes. The rising incidence of prostate cancer is primarily due to an aging population and increased use of screening methods like prostate-specific antigen (PSA) testing, which lead to higher detection rates. Prostate cancer drugs can be beneficial in treating prostate cancer by targeting specific changes inside prostate cancer cells that help them grow. They work differently from chemotherapy and hormone therapy drugs. For instance, in January 2023, according to the American Cancer Society, a US-based voluntary health organization dedicated to eliminating cancer, it was estimated that there were about 288,300 new cases of prostate cancer and about 34,700 deaths from prostate cancer. About 1 man in 8 will be diagnosed with prostate cancer during his lifetime. Therefore, the rising incidence of cancer is driving the growth of the prostate cancer drugs industry.

Key Players In The Global Prostate Cancer Drugs Market

Major companies operating in the prostate cancer drugs market are Astellas Pharma Inc., AstraZeneca PLC, Johnson & Johnson, Sanofi S.A., Bayer AG, Abbott Laboratories, Pfizer Inc., Novartis International AG, F. Hoffmann-La Roche Ltd., Tolmar Inc., AbbVie Inc., Siemens Healthineers AG, Genomic Health Inc., OPKO Health Inc., Siemens Healthcare GmbH, MDxHealth SA, Myriad Genetics Inc., Janssen Biotech Inc., Clovis Oncology Inc., Merck Sharp & Dohme Corp., Dendreon Corporation, Ferring Pharmaceuticals Inc., Ipsen Biopharmaceuticals Inc., Merck & Co. Inc., Eli Lilly and Company Inc., Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Novartis AG, Amgen Inc., Regeneron Pharmaceuticals Inc., Exelixis Inc.

Global Prostate Cancer Drugs Market Trends and Insights

Major companies operating in the prostate cancer drugs market integrate their efforts in introducing new products and getting them approved by federal agencies to maximize their revenues in the market. The drug development and approval process is a lengthy and complex process, and it is essential for drug sponsors to understand the regulatory controls and marketing pathways needed to ensure reasonable assurance of safety and effectiveness. For instance, in June 2023, AstraZeneca PLC, a UK-based pharmaceutical company, and Merck & Co. Inc., a US-based pharmaceutical company, announced the United States Food and Drug Administration's (USFDA), a US-based federal agency of the Department of Health and Human Services, approval of LYNPARZA (olaparib) Plus Abiraterone and Prednisone or Prednisolone for Treatment of Adult Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC). LYNPARZAplus abi/pred demonstrated clinically significant improvements in both radiographic progression-free survival (rPFS) and overall survival (OS) compared to abi/pred alone in patients with BRCAm mCRPC, according to an exploratory subgroup analysis of the Phase 3 PROpel trial, which served as the foundation for this approval.

What Are Latest Mergers And Acquisitions In The Prostate Cancer Drugs Market?

In March 2024, Johnson & Johnson, a US-based pharmaceutical industry company, acquired Ambrx Biopharma Inc. for an undisclosed amount. Through this acquisition, Johnson & Johnson aims to develop targeted oncology therapeutics using Ambrx’s proprietary ADC technology, which combines highly specific monoclonal antibodies with potent chemotherapeutic agents. This approach enhances the precision of cancer treatments, minimizing common chemotherapy side effects and transforming the treatment landscape for solid tumors, including prostate cancer. Ambrx Biopharma Inc. is a US-based biotechnology company specializing in the development of innovative therapies, including prostate cancer drugs.

Regional Insights

North America was the largest region in the prostate cancer drugs market in 2025. Middle East is expected to be the fastest-growing region in the prostate cancer drugs market during the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Prostate Cancer Drugs Market?

The prostate cancer drugs market consists of sales of Abiraterone Acetate, Apalutamide, and Bicalutamide. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Prostate Cancer Drugs Market Report 2026?

The prostate cancer drugs market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the prostate cancer drugs industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.